

Your Treatment Journal

Live in the positive

+CONNECTIONS
+POSSIBILITIES
+MOMENTS



VYLOY
zolbetuximab-clzb
for injection 100mg vial

What is VYLOY?

VYLOY is a prescription medicine used to treat adults with cancer of the stomach (gastric cancer) or cancer located where the esophagus joins the stomach (gastroesophageal junction cancer). VYLOY is used in combination with chemotherapy that contains fluoropyrimidine and platinum as the first treatment when your gastric or gastroesophageal junction cancer:

- cannot be removed with surgery or has spread to other parts of the body,
- is HER2-negative, **and**
- your tumor tests positive for “claudin (CLDN)18.2.”

It is not known if VYLOY is safe and effective in children.

SELECT SAFETY INFORMATION

Before receiving VYLOY, tell your healthcare provider about all of your medical conditions, including if you:

- have nausea or vomiting.
- are pregnant or plan to become pregnant. It is not known if VYLOY will harm your unborn baby. Tell your healthcare provider if you become pregnant during your treatment with VYLOY.
- are breastfeeding or plan to breastfeed. It is not known if VYLOY passes into your breast milk. Do not breastfeed during treatment with VYLOY and for 8 months after the last dose.

Tell your healthcare provider about all the medicines you take, including prescription and over-the-counter medicines, vitamins, and herbal supplements.

Please see [Important Safety Information](#) on pages 12-13 and read the [Patient Information](#).

Introduction

This journal can help you keep track of your VYLOY treatment journey by providing one place to record your questions, manage your infusion appointments, and write about how you're feeling.

The journal includes two sections:

Your Conversation Guide provides suggested **questions to ask your healthcare team** so you can get the most out of your care. You may have other questions than the ones listed here.

Tracking Your Treatment With VYLOY gives you a place to **manage infusion appointments** and record how you feel with each infusion. Bring it to doctor's visits to discuss with your healthcare team.



Your Conversation Guide



Questions to ask about your treatment

You are likely to have questions as you get ready to start VYLOY treatment. The questions below can help you start a dialogue with your healthcare team. You may have other questions than the ones listed here. Any question you have is important.

Why am I being given VYLOY?

How is VYLOY given?

What results have been seen with VYLOY?

What are the possible side effects of VYLOY that I should be aware of?

Your Conversation Guide



Questions to ask as you begin treatment

Knowing what to expect during infusions can help you be prepared. You may have other questions than the ones listed here. Any question you have is important.

What should I expect on a typical VYLOY infusion day?

What side effects may happen during or after an infusion?

What are the common side effects and how are they treated?

How can I prepare for my treatment days?

Your Conversation Guide



Questions to ask as you continue treatment

It's important to feel supported throughout your treatment journey. These questions can help you find resources available to you and your caregiver. You may have other questions than the ones listed here. Any question you have is important.

What support resources are available to me?

What support is available to caregivers?

Where can I find information about financial assistance and support programs?

Where can I turn for emotional support?

Notes

Use this space to write any additional notes or questions you may have.

Tracking Your Treatment With VYLOY

VYLOY[®]
zolbetuximab-clzb
for injection 100mg vial

Use this treatment tracker to manage upcoming appointments and to record how you feel with each infusion.

Bring it to doctor's visits and infusions to discuss with your healthcare team.

Example:

Infusion appointment details	Date.....xx/xx/xx..... Time.....XX AM/PM.....
	Location.....XXXXXXXXXX.....
	How am I getting there?.....XXXXXXXXXXXXXXXXXX.....
	XXXXXXXXXXXXXXXXXX.....
Post-infusion check-in	
How am I feeling overall?	Fill in your answers in this space
Did I experience side effects? When did they happen and how long did they last?	




Infusion appointment details

Date..... Time.....

Location.....

How am I getting there?.....

.....



Post-infusion check-in

How am I feeling overall?

Did I experience side effects? When did they happen and how long did they last?

What do I want to remember for my next infusion?

What do I want to ask my healthcare team?

Infusion appointment details

Date..... Time.....

Location.....

How am I getting there?.....

.....



Post-infusion check-in

How am I feeling overall?

Did I experience side effects? When did they happen and how long did they last?

What do I want to remember for my next infusion?

What do I want to ask my healthcare team?

Infusion appointment details

Date..... Time.....

Location.....

How am I getting there?.....

.....



Post-infusion check-in

How am I feeling overall?

Did I experience side effects? When did they happen and how long did they last?

What do I want to remember for my next infusion?

What do I want to ask my healthcare team?

Infusion appointment details

Date..... Time.....

Location.....

How am I getting there?.....

.....



Post-infusion check-in

How am I feeling overall?

Did I experience side effects? When did they happen and how long did they last?

What do I want to remember for my next infusion?

What do I want to ask my healthcare team?

What is VYLOY?

VYLOY is a prescription medicine used to treat adults with cancer of the stomach (gastric cancer) or cancer located where the esophagus joins the stomach (gastroesophageal junction cancer). VYLOY is used in combination with chemotherapy that contains fluoropyrimidine and platinum as the first treatment when your gastric or gastroesophageal junction cancer:

- cannot be removed with surgery or has spread to other parts of the body,
- is HER2-negative, **and**
- your tumor tests positive for “claudin (CLDN)18.2.”

It is not known if VYLOY is safe and effective in children.

IMPORTANT SAFETY INFORMATION

Before receiving VYLOY, tell your healthcare provider about all of your medical conditions, including if you:

- have nausea or vomiting.
- are pregnant or plan to become pregnant. It is not known if VYLOY will harm your unborn baby. Tell your healthcare provider if you become pregnant during your treatment with VYLOY.
- are breastfeeding or plan to breastfeed. It is not known if VYLOY passes into your breast milk. Do not breastfeed during treatment with VYLOY and for 8 months after the last dose.

Tell your healthcare provider about all the medicines you take, including prescription and over-the-counter medicines, vitamins, and herbal supplements.

What are the possible side effects of VYLOY?

VYLOY may cause serious side effects, including:

- **Allergic reactions, including anaphylaxis and infusion-related reactions.** Allergic reactions are common during treatment with VYLOY and can sometimes be serious. Serious allergic reactions can happen during or after your VYLOY infusion, including life-threatening allergic reactions, and infusion-related reactions. Your healthcare provider will monitor you during your infusion and for 2 hours after or longer if needed. Tell your healthcare provider or nurse or get emergency medical help right away if you get any of the following symptoms of a serious allergic reaction during or after your infusion of VYLOY:
 - itchy, raised bumps on the skin (hives)
 - coughing that does not go away
 - nausea or vomiting
 - stomach (abdominal) pain
 - increased saliva
 - breathing problems such as wheezing
 - throat tightness or change in voice
 - fever
 - chest discomfort
 - chills or shaking
 - back pain

What are the possible side effects of VYLOY? (cont.)

VYLOY may cause serious side effects, including:

- **Severe nausea and vomiting.** Nausea and vomiting are common during treatment with VYLOY and can sometimes be severe. Nausea and vomiting happened more often during the first treatment cycle. Before you receive each VYLOY infusion, your healthcare provider will give you medicines to help prevent nausea and vomiting. Tell your healthcare provider right away if nausea or vomiting does not go away or gets worse.

The most common side effects of VYLOY include:

- tiredness
- decreased appetite
- diarrhea
- tingling or numbness of the arms or legs
- stomach (abdominal) pain
- constipation
- decreased weight
- fever
- decreased white blood cells, red blood cells and platelets
- decreased protein (albumin) in the blood
- changes in kidney function tests
- changes in blood sugar (glucose)
- changes in liver functions tests
- changes in body salts (electrolytes) in your blood

If you have certain side effects, your healthcare provider may slow the rate of your infusion, temporarily stop or completely stop treatment with VYLOY. These are not all of the possible side effects of VYLOY. Call your doctor for medical advice about side effects. You may report side effects to the FDA at [1-800-FDA-1088](tel:1-800-FDA-1088) or www.fda.gov/medwatch.

VYLOY[®]
zolbetuximab-clzb
for injection 100mg vial



.....

Visit [VYLOY.com](https://www.vyloy.com) to learn more

.....

Please see [Important Safety Information](#) on pages 12-13 and read the [Patient Information](#).



© 2024 Astellas Pharma US, Inc. All rights reserved. MAT-US-ZOL-2024-00407 03/24
VYLOY, Astellas, and the flying star logo are registered trademarks of Astellas Pharma Inc.

PATIENT INFORMATION

VYLOY® (vye-LOY)
(zolbetuximab-clzb)
for injection

What is VYLOY?

VYLOY is a prescription medicine used to treat adults with cancer of the stomach (gastric cancer) or cancer located where the esophagus joins the stomach (gastroesophageal junction cancer). VYLOY is used in combination with chemotherapy that contains fluoropyrimidine and platinum as the first treatment when your gastric or gastroesophageal junction cancer

- cannot be removed with surgery or has spread to other parts of the body,
- is HER2-negative, **and**
- your tumor tests positive for “claudin (CLDN)18.2.”

It is not known if VYLOY is safe and effective in children.

Before receiving VYLOY, tell your healthcare provider about all of your medical conditions, including if you:

- have nausea or vomiting.
- are pregnant or plan to become pregnant. It is not known if VYLOY will harm your unborn baby. Tell your healthcare provider if you become pregnant during your treatment with VYLOY.
- are breastfeeding or plan to breastfeed. It is not known if VYLOY passes into your breast milk. Do not breastfeed during treatment with VYLOY and for 8 months after the last dose.

Tell your healthcare provider about all the medicines you take, including prescription and over-the-counter medicines, vitamins, and herbal supplements.

How will I receive VYLOY?

- VYLOY will be given to you by intravenous (IV) infusion into your vein.
- Your healthcare provider will decide how much VYLOY you will receive.
- You will usually receive VYLOY every 2 or 3 weeks based on the chemotherapy chosen by your healthcare provider.
- Your healthcare provider will decide how many treatments you need.
- Your healthcare provider may do blood tests during treatment with VYLOY.

What are the possible side effects of VYLOY?

VYLOY may cause serious side effects, including:

- **Allergic reactions, including anaphylaxis and infusion related reactions.** Allergic reactions are common during treatment with VYLOY and can sometimes be serious. Serious allergic reactions can happen during or after your VYLOY infusion, including life-threatening allergic reactions, and infusion-related reactions. Your healthcare provider will monitor you during your infusion and for 2 hours after or longer if needed. Tell your healthcare provider or nurse or get emergency medical help right away if you get any of the following symptoms of a serious allergic reaction during or after your infusion of VYLOY:
 - itchy, raised bumps on the skin (hives)
 - coughing that does not go away
 - nausea or vomiting
 - stomach (abdominal) pain
 - increased saliva
 - breathing problems such as wheezing
 - throat tightness or change in voice
 - fever
 - chest discomfort
 - chills or shaking
 - back pain
- **Severe nausea and vomiting.** Nausea and vomiting are common during treatment with VYLOY and can sometimes be severe. Nausea and vomiting happened more often during the first treatment cycle. Before you receive each VYLOY infusion, your healthcare provider will give you medicines to help prevent nausea and vomiting. Tell your healthcare provider right away if nausea or vomiting does not go away or gets worse.

The most common side effects of VYLOY include:

- tiredness
- decreased appetite
- diarrhea
- tingling or numbness of the arms or legs
- stomach (abdominal) pain
- constipation
- decreased weight
- fever
- decreased white blood cells, red blood cells and platelets
- decreased protein (albumin) in the blood
- changes in kidney function tests
- changes in blood sugar (glucose)
- changes in liver function tests
- changes in body salts (electrolytes) in your blood

If you have certain side effects, your healthcare provider may slow the rate of your infusion, temporarily stop or completely stop treatment with VYLOY.

These are not all of the possible side effects of VYLOY.

Call your doctor for medical advice about side effects. You may report side effects to FDA at 1-800-FDA-1088.

General information about the safe and effective use of VYLOY.

Medicines are sometimes prescribed for purposes other than those listed in a Patient Information leaflet. You can ask your pharmacist or healthcare provider for information about VYLOY that is written for healthcare professionals.

What are the ingredients in VYLOY?

Active ingredient: zolbetuximab-clzb

Inactive ingredients: arginine, polysorbate 80, and sucrose. Phosphoric acid to adjust pH.

Manufactured by:
Astellas Pharma US, Inc.
Northbrook, Illinois 60062

U.S. License 2124
©2023 Astellas Pharma US, Inc.

For more information, go to www.VYLOY.com or call 1-888-727-7003.

This Patient Information has been approved by the U.S. Food and Drug Administration.

Issued: 12/2023